Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Pharmacological characterization of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2, 3-dihydro-1H-inden-2-yl]-2-propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulator.

Ward SE, Beswick P, Calcinaghi N, Dawson LA, Gartlon J, Graziani F, Jones DN, Lacroix L, Selina Mok MH, Oliosi B, Pardoe J, Starr K, Woolley ML, Harries MH.

Br J Pharmacol. 2017 Mar;174(5):370-385. doi: 10.1111/bph.13696. Epub 2017 Jan 31.

PMID:
28009436
2.

Autoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implications.

Pollak TA, Beck K, Irani SR, Howes OD, David AS, McGuire PK.

Psychopharmacology (Berl). 2016 May;233(9):1605-21. doi: 10.1007/s00213-015-4156-y. Epub 2015 Dec 14. Review.

3.

Re-conceptualizing ASD Within a Dimensional Framework: Positive, Negative, and Cognitive Feature Clusters.

Foss-Feig JH, McPartland JC, Anticevic A, Wolf J.

J Autism Dev Disord. 2016 Jan;46(1):342-51. doi: 10.1007/s10803-015-2539-x.

4.

Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.

Iwata Y, Nakajima S, Suzuki T, Keefe RS, Plitman E, Chung JK, Caravaggio F, Mimura M, Graff-Guerrero A, Uchida H.

Mol Psychiatry. 2015 Oct;20(10):1151-60. doi: 10.1038/mp.2015.68. Epub 2015 Jun 16. Review.

5.

Performance enhancement at the cost of potential brain plasticity: neural ramifications of nootropic drugs in the healthy developing brain.

Urban KR, Gao WJ.

Front Syst Neurosci. 2014 May 13;8:38. doi: 10.3389/fnsys.2014.00038. eCollection 2014. Review.

6.

Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system.

Gruber O, Chadha Santuccione A, Aach H.

Front Psychiatry. 2014 Apr 3;5:32. doi: 10.3389/fpsyt.2014.00032. eCollection 2014. Review.

7.

Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments.

Rubio MD, Drummond JB, Meador-Woodruff JH.

Biomol Ther (Seoul). 2012 Jan;20(1):1-18. doi: 10.4062/biomolther.2012.20.1.001. Review.

8.

Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy.

Choi KH, Wykes T, Kurtz MM.

Br J Psychiatry. 2013 Sep;203(3):172-8. doi: 10.1192/bjp.bp.111.107359. Review. Erratum in: Br J Psychiatry. 2013 Nov;203(5):392.

9.

Synaptic regulation of affective behaviors; role of BDNF.

Ninan I.

Neuropharmacology. 2014 Jan;76 Pt C:684-95. doi: 10.1016/j.neuropharm.2013.04.011. Epub 2013 Jun 6. Review.

10.

Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.

Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA.

Curr Top Med Chem. 2013;13(1):26-54. Review.

11.

Beyond dopamine: glutamate as a target for future antipsychotics.

Sendt KV, Giaroli G, Tracy DK.

ISRN Pharmacol. 2012;2012:427267. doi: 10.5402/2012/427267. Epub 2012 Jul 5.

12.

Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

McCullumsmith RE, Hammond J, Funk A, Meador-Woodruff JH.

Curr Pharm Biotechnol. 2012 Jun;13(8):1535-42. Review.

13.

The neuropharmacology of implicit learning.

Uddén J, Folia V, Petersson KM.

Curr Neuropharmacol. 2010 Dec;8(4):367-81. doi: 10.2174/157015910793358178.

14.

Newer molecules in the treatment of schizophrenia: A clinical update.

Ghosh A, Chakraborty K, Mattoo SK.

Indian J Pharmacol. 2011 Apr;43(2):105-12. doi: 10.4103/0253-7613.77334.

15.

Structural and functional analysis of two new positive allosteric modulators of GluA2 desensitization and deactivation.

Timm DE, Benveniste M, Weeks AM, Nisenbaum ES, Partin KM.

Mol Pharmacol. 2011 Aug;80(2):267-80. doi: 10.1124/mol.110.070243. Epub 2011 May 4.

16.

Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.

Sommer IE, Begemann MJ, Temmerman A, Leucht S.

Schizophr Bull. 2012 Sep;38(5):1003-11. doi: 10.1093/schbul/sbr004. Epub 2011 Mar 21. Review.

17.

The treatment of cognitive impairment in schizophrenia.

Goff DC, Hill M, Barch D.

Pharmacol Biochem Behav. 2011 Aug;99(2):245-53. doi: 10.1016/j.pbb.2010.11.009. Epub 2010 Nov 27. Review.

18.

Glutamate receptor ion channels: structure, regulation, and function.

Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R.

Pharmacol Rev. 2010 Sep;62(3):405-96. doi: 10.1124/pr.109.002451. Review. Erratum in: Pharmacol Rev. 2014 Oct;66(4):1141.

19.

BDNF upregulation rescues synaptic plasticity in middle-aged ovariectomized rats.

Kramár EA, Chen LY, Lauterborn JC, Simmons DA, Gall CM, Lynch G.

Neurobiol Aging. 2012 Apr;33(4):708-19. doi: 10.1016/j.neurobiolaging.2010.06.008. Epub 2010 Jul 31.

20.

Challenges for and current status of research into positive modulators of AMPA receptors.

Ward SE, Bax BD, Harries M.

Br J Pharmacol. 2010 May;160(2):181-90. doi: 10.1111/j.1476-5381.2010.00726.x. Review.

Supplemental Content

Support Center